Impetigo in children: what clears it, and why guidelines now start with antiseptic

Impetigo, the crusted "school sores" that spread easily among children, clears reliably with treatment — topical antibiotics beat placebo in the pooled trials — but current UK guidance deliberately does not reach for an antibiotic first for a mild case [s1][s2]. For localised infection in a child who is otherwise well, the recommended starting point is an antiseptic, hydrogen peroxide cream, with antibiotics held back for cases that are more widespread or that do not settle [s2]. The shift is not because antibiotics stopped working; it is a calculated choice to slow resistance.

What impetigo is

Impetigo is a common, superficial bacterial skin infection, most often caused by Staphylococcus aureus and Streptococcus pyogenes, and most frequently seen in children [s1]. It shows as red sores, often around the nose and mouth, that rupture and form a honey-coloured crust, and it passes readily by contact, which is why nurseries and schools take it seriously. The non-bullous form is the usual one; a bullous form produces fluid-filled blisters. Many cases would eventually resolve on their own, but because it is contagious and occasionally leads to complications, treatment is standard.

What the trials show works

The most complete evidence is a Cochrane review of 68 randomised trials in 5,578 participants, covering 50 different treatments [s1]. Topical antibiotics clearly outperformed placebo, with a pooled risk ratio for cure of 2.24 (95% confidence interval 1.61 to 3.13) across six studies in 575 participants [s1]. Among the topical options, there was no clear winner between the two most studied, mupirocin and fusidic acid (risk ratio 1.03, 95% confidence interval 0.95 to 1.11) [s1]. Notably, topical mupirocin was at least as good as — slightly better than — oral erythromycin (risk ratio 1.07, 95% confidence interval 1.01 to 1.13), evidence that for limited disease a cream can match a tablet without exposing the whole body to an antibiotic [s1]. The review also found meaningful differences between oral agents, with penicillin inferior to erythromycin, underscoring that not all antibiotics are interchangeable here [s1].

Why guidance leads with hydrogen peroxide

NICE guidance on impetigo prescribing turns that evidence into a stewardship-first pathway. For localised non-bullous impetigo in someone who is not systemically unwell and not at high risk of complications, it recommends considering hydrogen peroxide 1% cream — an antiseptic, not an antibiotic — applied two or three times a day for five days [s2]. If hydrogen peroxide is unsuitable, for example around the eyes, or ineffective, the first-choice topical antibiotic is fusidic acid 2%, three times a day for five days, with mupirocin 2% reserved for suspected or confirmed fusidic acid resistance [s2]. A short course of a topical or oral antibiotic is offered for widespread infection, and for penicillin allergy the guidance names clarithromycin at 250 mg twice a day for five days [s2]. A five-day course is usually appropriate, extended to seven only on clinical judgement [s2].

The logic is antimicrobial stewardship: impetigo is common, much of it is mild, and defaulting every case to an antibiotic drives resistance without improving outcomes for the mildest infections. Choosing an antiseptic where it will do keeps antibiotics effective for where they are needed — the same pressure shaping prescribing across primary care.

How to read this

The evidence gives a clear order of operations. Topical antibiotics work and, for limited disease, spare a child systemic treatment; for the mildest localised cases an antiseptic is now the recommended first step; oral antibiotics are for widespread or more serious infection [s1][s2]. Because impetigo often takes hold in skin already broken by scratching, it also overlaps with conditions that damage the skin barrier — see what helps childhood eczema — and it sits among the everyday childhood complaints, like hand, foot and mouth disease and head lice, where the useful question is which treatments actually have evidence behind them.

This article is informational and not medical advice; a suspected skin infection in a child should be assessed by a qualified clinician, who prescribes and doses any treatment.